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Purpose: There are still debates on the benefit of mass screening for prostate can-
cer (PCA) by prostate specific antigen (PSA) testing, and on systemized surveil-
lance protocols according to PSA level. Furthermore, there is a paucity of literature 
on current practice patterns according to PSA level in the Korean urologic field. 
Here, we report the results of a nationwide, multicenter, retrospective chart-review 
study. Materials and Methods: Overall 2122 Korean men (>40 years old, PSA 
>2.5 ng/mL) were included in our study (from 122 centers, in 2008). The primary 
endpoint was to analyze the rate of prostate biopsy according to PSA level. Sec-
ondary aims were to analyze the detection rate of PCA, the clinical features of pa-
tients, and the status of surveillance for PCA according to PSA level. Results: The 
rate of prostate biopsy was 7.1%, 26.3%, 54.2%, and 64.3% according to PSA lev-
els of 2.5-3.0, 3.0-4.0, 4.0-10.0, and >10.0 ng/mL, respectively, and the PCA de-
tection rate was 16.0%, 22.2%, 20.2%, and 59.6%, respectively. At a PSA level 
>4.0 ng/mL, we found a lower incidence of prostate biopsy in local clinics than in 
general hospitals (21.6% vs. 66.2%, respectively). A significant proportion 
(16.6%) of patients exhibited high Gleason scores (≥8) even in the group with low 
PSA values (2.5-4.0 ng/mL). Conclusion: We believe that the results from this na-
tionwide study might provide an important database for the establishment of prac-
tical guidelines for the screening and management of PCA in Korean populations.
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INTRODUCTION
Prostate cancer (PCA) is the most common male cancer in Western countries.1,2 In 
Korea, it is the fifth most common cancer in men, and its incidence is the most rap-
idly increasing among all cancers.3,4 Although the level of serum prostate-specific 
antigen (PSA) is considered the most useful currently available tumor marker for 
prostate cancer,5-7 it clearly has some limitations,6,8,9 including racial differences.10 
Moreover, the benefit of mass screening by PSA testing and systemized surveil-
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or a history of prostate surgery and those who had previ-
ously been taking a 5 alpha-reductase inhibitor, androgen 
blocker, or saw palmetto.
PSA assay
Serum PSA was assayed using a chemiluminescence meth-
od with commercially available kits that varied among the 
different institutions (Elecsys®, Roche, Switzerland; Archi-
tect®, Abbott, IL, USA; Immulite®, DPC, Bad Nauheim, 
Germany). Regardless of different institutions, all assays 
measured equimolar total PSA and were then calibrated 
against the World Health Organization (WHO) buffer-based 
reference material to ensure the accuracy of the results of 
any determination of PSA. 
Study endpoints and assessments
The primary endpoint of this study was to analyze the rate 
of prostate biopsy performed by Korean urologists accord-
ing to PSA level. Secondary aims were 1) to analyze the 
detection rate of PCA according to PSA level, 2) to analyze 
the clinical features (age, comorbidity, familial PCA, etc.) 
of patients according to PSA level, and 3) to analyze the 
status of surveillance for PCA according to PSA level. Ad-
ditionally, we analyzed the number of biopsy cores. 
Statistical analysis
Analysis of prostate biopsy rate according to PSA level and 
percentage of the patients who had PCA according to PSA 
level was performed using the chi-square test and Cocharn-
Armitage test, respectively. Statistical analysis was per-
formed with software SAS (version 9.2). Results were con-
sidered significant at p<0.05. 
 
RESULTS
 
Patient disposition
The 122 centers included 63 general hospitals (1627 men, 
76.2%) and 59 local clinics (510 men, 23.8%). The regional 
distribution of our study population was as follows: 603 
(28.4%) in Seoul, 498 (23.5%) in Gyeonggi/Incheon, 478 
(22.5%) in Gyeongsang, 281 (13.2%) in Jella and Jeju, 218 
(10.3%) in Chungcheong, and 44 (2.1%) in Gangwon areas. 
From a total of 2137 men, 2122 were included in our study. 
The main reasons for exclusion were low PSA (<2.5 ng/mL, 
n=2), young age (<40 years, n=1), and recent history of 
medication (5-alpha reductase inhibitors, anti-androgen, or 
lance protocols according to PSA level are still under debate. 
In Korean men, the incidence of PCA to date has been 
quite low compared with that of white men,11-13 and it has 
been suggested that the age-specific PSA reference ranges 
for Korean men might be lower than those for white,14,15 
Japanese,10 and Taiwanese men.16 Accordingly, various re-
ports11,14,17 have suggested that the cut-off value of PSA 
should be lowered, or age-specific references should be con-
sidered in Korean men. As for PSA screening, its benefit is 
also the subject of ongoing debates in European (ERSPC) 
and US studies.18,19
Since there is a paucity of literature providing basic infor-
mation to establish practical guidelines for Korean men, we 
performed a nationwide survey of the current strategies used 
by Korean urologists for surveillance and management of 
PCA according to PSA level and report the survey results 
herein. To our knowledge, this is the first nation-wide study 
including data from general hospitals and local clinics on 
this issue in Korea.
MATERIALS AND METHODS
　　　
Study design
We conducted a nationwide, multicenter, retrospective study 
defining the current spectrum of practice patterns used by 
Korean urologists for the management of patients accord-
ing to PSA level (sponsored by GSK Inc., Seoul, Korea). 
Data were collected by retrospectively reviewing the charts, 
from 122 referral hospitals (63 general hospitals and 59 lo-
cal clinics) in Korea from January 2008 to December 2008. 
The protocol was approved by the ethics committees of the 
participating centers. Based on the assumptions that a biop-
sy rate would be 40.6%4 (PSA >4.0 ng/mL), that the num-
ber of patients with PSA <4.0 ng/mL would be 3.2 times 
greater than those with PSA >4.0 ng/mL, and that 30% of 
patients would not be eligible for inclusion because of the 
nature of retrospective study, a sample size of at least 2215 
subjects was required to obtain a power of 90%, with a type 
1 error of 0.05 (for a two-sided test).
Study population
A total of 2122 men with a PSA level of >2.5 ng/mL and 
>40 years old who had visited the hospital were eligible for 
the study. We excluded patients with urinary tract infection, 
a history of acute urinary retention, and acute prostatitis, 
and those who had a previous diagnosis of prostate cancer 
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ANOVA test) (Table 1).
We also analyzed IPSS, and PSA according to age (Table 
2). IPSS was found to be higher with increasing age (p= 
0.032). PSA also increased with age (p=0.021). 
The median interval from PSA detection to prostate biop-
sy was 4.5 days. The distribution of GS according to PSA 
level is shown in Table 3. 
Practice patterns
Prostate biopsy rate and PCA detection rate (Table 4)
The rate of prostate biopsy according to PSA level was 
7.1%, 26.3%, 54.2%, and 64.3%, for PSA levels of 2.5-3.0 
ng/mL, 3.0-4.0 ng/mL, 4.0-10.0 ng/mL, and  >10.0 ng/mL, 
respectively. This correlation was also observed when we 
analyzed the biopsy rates of each age group according to 
PSA level. The PCA detection rate was 16.0%, 22.2%, 
20.2%, and 59.6%, respectively. When the PCA detection 
rate was analysed by dividing our patients according to PSA 
levels of 2.5-3.0 ng/mL, 3.0-10.0 ng/mL, and >10.0 ng/mL, 
the detection rates of 16.0%, 42.4%, and 59.6%, respective-
sopalmetto; n=12).
Patient demographics and characteristics
For the total patients in our study, the mean age was 66.2 
years, mean height was 167.4 cm, and mean weight was 
67.3 kg. The incidence of current smoking was 27.1%, and 
14.0% (n=42) of patients with PCA (n=300) had a positive 
family history of PCA. Baseline demographics and charac-
teristics according to PSA level are shown in Table 1. 
For the overall study population, the reasons for PSA test-
ing were as follows: suspicion of benign prostatic hyperpla-
sia (70.1%), suspicion of PCA (21.8%), regular follow-up 
(7.2%), acute prostatitis (5.8%), and others (1.6%). Among 
the study patients, 43.5% (924/2122) had comorbidity disor-
ders: hypertension (28.3%), diabetes (10.8%), cardiovascular 
disease (5.2%), cerebrovascular disease (3.9%), and sexual 
function disorders (1.2%). 
There was no significant difference in prostate volume 
according to PSA level (p=0.425) (Table 1). There was no 
significant difference in international prostate symptom 
scale (IPSS) score according to PSA level (p=0.36 from 
Table 1.  Patient Demographics and Characteristics
PSA (ng/mL)
2.5-3 (n=351) >3-3.5 (n=170) >3.5-4.0 (n=172) >4 (n=1429) Total (n=2122)
Age (yrs)
n 351 170 172 1428 2121
Mean (SD)   64.2 (9.3)   64.0 (9.9) 65.5 (9.7)   67.0 (9.6)   66.2 (9.7)
Height (cm)
n 138   80   66   657   941
Mean (SD) 169.0 (5.6) 167.5 (5.8) 167.4 (6.4) 167.0 (5.7) 167.4 (5.8)
Weight (kg)
n 141   81   69   679   970
Mean (SD)   70.1 (8.6)   67.1 (8.0) 66.8 (8.1)   66.9 (8.8)   67.3 (8.7)
Smoking
n 273 130 129 1145 1677
n (%)         79 (28.9)        48 (36.9) 40 (31.0)      288 (25.2)       455 (27.1)
IPSS score
n 149   76   88   645   958
Mean (SD)    17.5 (7.2)   16.6 (7.6) 18.9 (8.1)   18.0 (7.8)   17.9 (7.7)
PV (gm)
n   43   29   22   211   305
Mean (SD)     35.2 (11.0)   35.1 (7.9) 36.0 (9.4)     36.7 (11.2)      36.3 (10.7)
IPSS, international prostate symptom score; PSA, prostate-specific antigen; PV, prostate volume; SD, standard deviation.
Table 2.  IPSS and PSA according to Patient Age
Age
40-49 50-59 60-69 70-79 >80
IPSS* score
n 51 169 370 317 50
Mean (SD) 16.6 (6.9) 17.0 (7.6) 17.6 (7.5) 18.6 (8.0) 20.1 (7.6)
Median 17.0 18.0 18.0 19.0 22.0
PSA* (ng/mL)
n 128 366 797 682 148
Mean (SD) 6.4 (8.0) 8.7 (21.6) 10.8 (39.4) 15.6 (53.0) 40.5 (177.7)
Median 4.4 4.9 5.1 5.9 7.0
IPSS, international prostate symptom score; PSA, prostate specific antigen; ANOVA, analysis of variance; SD, standard deviation.
*p<0.05 (from ANOVA test).
Practice Patterns for Screening of Prostate Cancer 
Yonsei Med J   http://www.eymj.org   Volume 53   Number 6   November 2012 1139
baseline PSA level (54.1%, 60.0%, 64.0%, and 73.8%, for 
PSA levels of 2.5-3.0 ng/mL, >3.0-3.5 ng/mL, >3.5-4.0 ng/
mL, and >4.0 ng/mL, respectively; p<0.0001 from Co-
chran-Armitage trend test). Moreover, the interval from ini-
tial testing to follow-up testing of PSA value decreased 
with increasing baseline PSA level (mean 4.6 months vs. 
8.6 months for PSA level of  >4.0 ng/mL vs. 2.5-4.0 ng/mL, 
respectively).
Number of biopsy cores
Among 800 patients who had biopsies, the number of biop-
sy cores was 12 in 345 patients (43.1%), 10 in 169 patients 
(21.1%), 6 in 135 patients (16.8%), and 8 in 82 patients 
(10.2%).
DISCUSSION
Since Catalona, et al.20 addressed that serum PSA concentra-
tion of 4.0 ng/mL should be used as a general guideline for 
biopsy in all age groups, there have been numerous studies 
on the PCA detection rate according to PSA level. Because 
it is a matter of racial difference, it is truly important to stan-
ly, were observed.
Comparison of general hospitals (GH) and local clinics (LC)
We analyzed the biopsy rate according to GH and LC and 
the incidence of top hospital referral. In our analysis, the bi-
opsy rate was higher in GH than in LC for all PSA levels. 
In particular, the rate of biopsy was much higher in GH 
(66.2%) than in LC (21.6%) at a PSA level >4.0 ng/mL.  
We also compared the detection rate of PCA according to 
PSA level between GH and LC: for a PSA level of 2.5-4.0 
ng/mL, the detection rate of PCA was 15.1% (16/106) in 
GH and 44.4% (4/9) in LC. However, this result was limited 
by the small number of patients in LC. For a PSA level >4.0 
ng/mL, the detection rate of PCA was similar between GH 
and LC [34.3% (260/759) in GH and 32.8% (20/61) in LC].
Follow-up 
Follow-up of total PSA level was performed in 67.9% (1440/ 
2122) of patients, and follow-up of free PSA level was per-
formed in 47.7% (132/277). Follow-up of uroflowmetry (Q 
max) and post-void residual urine was performed in 14.9% 
(120/808) and 15% (114/760) of patients, respectively. The 
rate of follow-up for PSA value increased with increasing 
Table 3. Distribution of Biopsy Gleason Score according to Serum PSA Level
Biopsy Gleason score 
  No. patients <6 6 7 ≥8 Total
PSA (ng/mL)
    2.5-3.0 0 (0)   2 (50.0)      1 (25.0)     1 (25.0)     4 (100.0)
    3.0-4.0 0 (0) 14 (70.0)      3 (15.0)     3 (15.0)   20 (100.0)
    >4.0  18 (6.5) 63 (22.8)   96 (34.7)   99 (35.8) 276 (100.0)
    Total  18 (6.0) 79 (26.4) 100 (33.3) 103 (34.3) 300 (100.0)
PSA, prostate specific antigen.
Data in parenthesis represents percentage.
Table 4. Prostate Biopsy Rate and Cancer Detection Rate by Age and Serum PSA Level
                 No. patients No. biopsied (%) No. cancer Cancer detection rate (%)
Age (yrs)
    40-49   128   38 (29.6)     4 10.5
    50-59   366 172 (46.9)   40 23.2  
    60-69   798 379 (47.5) 113 29.8                  
    70-79   682 286 (41.9) 112 39.1               
    >80   148   59 (39.8)   31 20.9           
    Total 2122 934 (44.0) 300 14.1              
PSA (ng/mL)
    2.5-3.0   351 25 (7.1)     4 16.0   
    3.0-4.0   342   90 (26.3)   20 22.2            
    4.0-10.0   994 539 (54.2) 109 20.2                
    >10.0   435 280 (64.3) 167 59.6            
    Total 2122 934 (44.0) 300 14.1           
PSA, prostate specific antigen.
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similar to (or silghtly greater than) that of patients with PSA 
of 4.0-10.0 ng/mL (22.2% vs. 20.2%): the PCA detection 
rates of 16.0%, 42.4%, and 59.6% were found for PSA lev-
els of 2.5-3.0 ng/mL, 3.0-10.0 ng/mL, >10.0 ng/mL, respec-
tively. For GS, 34.4% (103/300) (Table 3) of the cancers 
were GS 8 to 10 in the biopsy, which was significantly 
higher proportion than that of western countries.4,23-26 In our 
study, a significant proportion (16.6%) of the patients had 
PCA with GS >8 even at the level of PSA <4 ng/mL. There-
fore, these findings on the detection rates and GS distribu-
tion in Korean men are in good agreement with the previ-
ous reports,11,14,17 emphasizing the need for lowering the 
cut-off value of PSA in Korean men. 
The main concern of this nationwide study was to show 
the biopsy incidence and practice patterns, including PSA 
follow-up according to PSA level, in current urologic field 
in Korea. Considering current inconclusiveness on this is-
sue (including the role of PSA screening), we believe that 
our present results, including the survey result on the biop-
sy incidence by Korean urologists, detection rate of PCA, 
and GS distribution according to PSA level, can be an im-
portant database for Asian urologists, as well as Korean.   
Our study is limited by the fact that we evaluated the rate 
of prostate biopsy by dividing only PSA level and digital 
rectal examination finding was not considered. This is a 
limitation of this retrospective, chart-reviewing study. An-
other limitation is that some variations in the PSA value 
might have occurred: despite the narrowing in differences 
among PSA assays since the introduction of the WHO 
96/670 reference preparation, interchangeability of PSA 
values obtained by commercial PSA assays remains inade-
quate.27
In conclusion, we believe that the results from this nation-
wide study might provide an important database for the es-
tablishment of practical guidelines for the screening and 
management of PCA in Korean populations.
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